Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 12—December 2010
Letter

Ribavirin for Lassa Fever Postexposure Prophylaxis

Christiane M. Hadi, Augustine Goba, Sheik Humarr Khan, James Bangura, Mbalu Sankoh, Saffa Koroma, Baindu Juana, Alpha Bah, Mamadou Coulibaly, and Daniel G. BauschComments to Author 
Author affiliations: Author affiliations: Tulane University Health Sciences Center, New Orleans, Louisiana, USA (C.M. Hadi, D.G. Bausch); Ministry of Health and Sanitation, Kenema, Sierra Leone (A. Goba, S.H. Khan, J. Bangura, M. Sankoh, S. Koroma, B. Juana); International Center for Research on Tropical Infections, N’Zérékoré, Guinea (A. Bah, M. Coulibaly); Tulane School of Public Health and Tropical Medicine, New Orleans (D.G. Bausch)

Main Article

Figure

Adverse effects reported by 23 persons who took oral ribavirin prophylactically after potential exposure to Lassa virus, Sierra Leone, 2004.

Figure. Adverse effects reported by 23 persons who took oral ribavirin prophylactically after potential exposure to Lassa virus, Sierra Leone, 2004.

Main Article

Page created: August 29, 2011
Page updated: August 29, 2011
Page reviewed: August 29, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external